Universe Pharmaceutical Class AUPC
13F holders, Q2 2024 (June 30)2holders
0new positions
0sold out
$2.36avg. 13F price*
At the end of Q2 2024, 2 institutions reported holding Universe Pharmaceutical Class A (UPC) in their 13F filings, unchanged from Q1 2024. 0 opened new positions and 0 sold out. The largest holders were UBS Group AG ($13K) and Acadian Asset Management LLC ($0).
- Company
- Universe Pharmaceutical Class A
- CUSIP
- G9442G112
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 4,148 shares bought, net +4,148 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| UBS Group AG | 0.00% | Add +380.9% | 5,237 | $13K |
| Acadian Asset Management LLC | 0.00% | No change | 300 | $0 |
"% of holder's portfolio" is UPC's weight in each manager's 13F, not the share of Universe Pharmaceutical Class A the manager owns.